The addition of tumor treating fields to first-line chemotherapy can extend overall survival without increasing systemic toxicity among patients with locally advanced pancreatic cancer, according to new findings from the phase 3 PANOVA-3 trial (LBA4005).

CAN-2409 plus valacyclovir significantly improves disease-free survival compared with placebo plus valacyclovir combined with standard external beam radiation therapy with or without short-course androgen deprivation therapy in patients with intermediate- or high-risk localized prostate cancer, according to a phase 3 trial (Abstract 5000). The U.S. Food and Drug Administration has already granted both Fast Track designation and Regenerative Medicine Advanced Therapy designation to the therapy.

Combination nivolumab and relatlimab does not improve relapse-free survival over nivolumab monotherapy in patients with completely resected stage III/IV melanoma, according to results of the phase 3 RELATIVITY-098 trial (LBA9500).

First-line treatment with trastuzumab deruxtecan plus pertuzumab extends progression-free survival by more than 1 year compared with standard-of-care taxane plus trastuzumab/pertuzumab, according to initial results from the global DESTINY-Breast09 trial (LBA1008).

Dr. John Sweetenham shares highlights from Day 4 of the 2025 ASCO Annual Meeting, including new research on maintenance therapy in small cell lung cancer and a virtual reality psychosocial intervention for patients undergoing hematopoietic stem cell transplantation.